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6.1 GENERAL CONSIDERATIONS
6.1.1 Cytogenetic analyses of neoplastic blood and/or bone 
marrow–acquired clonal chromosomal abnormalities have been 
increasingly important in the clinical management of patients 
with hematological neoplasms. At time of diagnosis, cytogenetic 
abnormalities assist in the diagnosis of such disorders and can 
provide important prognostic information.1 Furthermore, cyto-
genetic analysis can provide crucial information regarding spe-
cific genetically defined subtypes of these neoplasms that have 
targeted therapies. At time of relapse, cytogenetic analysis can be 
used to confirm recurrence of the original neoplasm, detect clonal 
disease evolution, or uncover a new unrelated neoplastic process.
6.1.2 These cytogenetic analyses include conventional G-banded 
chromosome analysis, fluorescence in situ hybridization (FISH), 
and/or chromosomal microarray (CMA). Laboratories should 
work closely with oncologists and pathologists to determine the 
order of testing required to obtain relevant cytogenetic informa-
tion in a cost-effective manner.
6.1.3 Laboratories offering cytogenetic analyses for hemato-
logical neoplasms should be familiar with the various chromo-
somal abnormalities associated with the different neoplasms 
and their clinical significance. The laboratory should be able 
to provide a robust analytical and interpretative service for 
the various hematological neoplasms. All results should be, to 
the extent possible, interpreted in the context of the clinical, 
 pathologic, and molecular findings.1,2
6.1.4 Tissue processing, analytical variables, and turnaround 
time (TAT) should be determined by the laboratory based on 
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Cytogenetic analyses of hematological neoplasms are performed to 
detect and characterize clonal chromosomal abnormalities that have 
important diagnostic, prognostic, and therapeutic implications. At 
the time of diagnosis, cytogenetic abnormalities assist in the diag-
nosis of such disorders and can provide important prognostic infor-
mation. At the time of relapse, cytogenetic analysis can be used to 
confirm recurrence of the original neoplasm, detect clonal disease 
evolution, or uncover a new unrelated neoplastic process. This sec-
tion deals specifically with the standards and guidelines applicable to 
chromosome studies of neoplastic blood and bone marrow–acquired 
chromosomal abnormalities. 
This updated Section E6.1–6.4 has been incorporated into and super-
sedes the previous Section E6 in Section E: Clinical Cytogenetics 
of the 2009 Edition (Revised 01/2010), American College of Medi-
cal Genetics and Genomics Standards and Guidelines for Clinical 
Genetics Laboratories.
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the indication for cytogenetic referral (e.g., initial diagnosis 
versus follow-up studies, pre- versus posttransplant studies, 
and lymphoid versus myeloid malignancies) and the clinical 
application of the cytogenetic results (e.g., selection of therapy).
6.1.5 Molecular genetics analyses are essential for diagnosis 
of some hematological neoplasms, and several molecular muta-
tions, not detectable by cytogenetic analyses, provide important 
diagnostic and prognostic information. These are outside the 
scope of the current guidelines.
6.1.6 For quality assurance, the laboratory should monitor 
the numbers and types of hematological neoplasms received, 
percentage of cases with abnormal results, cell culture success 
rate, success rate of FISH and CMA studies, TAT, and corre-
lation of FISH and CMA data with G-banded chromosome 
analysis results.
6.2 SPECIMEN COLLECTION AND PROCESSING
6.2.1 Specimen collection
6.2.1.1 Only those cells involved in the neoplastic process will 
harbor the abnormalities being sought. Therefore, the specimen 
type and culture techniques utilized should optimize the prob-
ability of detecting an abnormal clone.
6.2.1.2 In most cases, bone marrow is the tissue of choice for 
cytogenetic analyses of suspected hematological neoplasms. 
In some circumstances, alternative specimens may be used, 
including the following:
a. Peripheral blood specimens may yield informative results 
when the circulating blast cell percentage is higher than 
10%. In general, the abnormal clone can be identified in 
such specimens, albeit not as often as in bone marrow. 
Peripheral blood or bone marrow can be used in chronic 
lymphocytic leukemia (CLL).
b. Bone marrow core biopsy specimens.
c. Bone marrow smears and core biopsy touch imprints can 
be used for interphase FISH.
d. Lymph node biopsy material or biopsy material from a 
suspected lymphoid mass are the preferred tissue in all 
lymphomas.
e. Cerebrospinal fluid.
f. Extramedullary leukemia (myeloid sarcoma, chloroma) 
tissue biopsy.
6.2.1.3 Specimens should be collected under sterile condi-
tions in sodium heparin tubes for chromosome and/or FISH 
analyses. Bone marrow aspirate and biopsy specimens should 
preferably be collected in an appropriate transport medium 
tube with sodium heparin. The concentration of sodium hepa-
rin should be ~20 U/ml of specimen (per either bone marrow 
volume alone or per total volume of bone marrow and trans-
port medium combined). EDTA tubes can be used for proce-
dures that require genomic DNA extraction.
6.2.1.4 The volume of bone marrow available will differ for 
adults and children. An approximate specimen of 1 to 3 ml 
should be requested. During specimen procurement, several 
draws are likely to be withdrawn. Because the first draw is more 
concentrated with neoplastic immature bone marrow cells, it is 
recommended that cytogenetics receive the first or second draw 
whenever possible.
6.2.1.5 Specimens should be received by the laboratory as 
soon as possible, ideally within 24 hours. Also, it is recom-
mended that specimens be maintained at ambient temperature 
during transit. Extreme temperatures should be avoided.
6.2.1.6 If the specimen size precludes cell culture and conven-
tional G-banded chromosome analysis, bone marrow smears 
or core biopsy touch imprints can be used for interphase FISH 
analysis.
6.2.2 Specimen processing
6.2.2.1 The laboratory should process the specimen as soon 
as possible after it is received. The methods that will be used to 
analyze the specimen should be determined prior to process-
ing whenever possible. If chromosome analysis is requested, 
cell culture will be required. If FISH and/or CMA analyses are 
requested, a portion of the specimen can be used for direct har-
vest of interphase cells and/or genomic DNA extraction.
6.2.2.2 If a bone marrow core biopsy is obtained, it should 
be disaggregated to generate a cell suspension. This can be 
achieved by mechanical mincing and/or enzymatic digestion 
using collagenase. Culture conditions are the same as those for 
a bone marrow aspirate.
6.2.2.3 Cell culture conditions should be optimized for the 
specific hematological neoplasm suspected:
a. Acute leukemias, including acute myeloid leukemia 
(AML), acute lymphoblastic leukemia (ALL), and 
acute biphenotypic leukemia: Unstimulated short-term 
cultures are recommended. If sufficient specimen is 
received, at least two cultures should be initiated, includ-
ing direct, overnight, and/or 24-hour cultures. In pediat-
ric ALL, an additional unstimulated 48-hour culture can 
be useful in characterizing the abnormal karyotype. The 
seeding density is usually 1 to 3 million cells per ml of 
medium.
b. Myelodysplastic syndromes (MDS) and myeloprolifera-
tive neoplasms (MPN): Same as acute leukemias.
c. Plasma cell dyscrasias, including multiple myeloma 
(MM) and plasma cell leukemia: Unstimulated 24- and 
72-hour cultures as well as 120-hour IL-4-stimulated 
culture are recommended.3 For FISH and/or CMA 
analyses, if the bone marrow plasma cells percentage 
(as determined by flow cytometry) is below a certain 
cutoff value, plasma cell separation is recommended to 
enrich for the CD138+ plasma cell fraction.4,5 The labo-
ratory needs to establish its cutoff value for plasma cell 
enrichment.
d. Chronic lymphoproliferative disorders: Depending on 
the immunophenotype, additional cultures with B- or 
T-cell mitogens may be helpful. In CLL and other mature 
B-cell neoplasms, CpG-oligonucleotide cell stimulation 
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is recommended and has been shown to enhance the 
detection of clonal chromosomal abnormalities.6,7
e. Well-differentiated T-cell disorders (e.g., T-cell leuke-
mias, T-cell lymphoma, Sézary syndrome, and mycosis 
fungoides): T-cell mitogens may be helpful.
6.3 ANALYSIS
6.3.1 Conventional G-banded chromosome analysis
6.3.1.1 Cell selection: metaphase cells should not be selected 
for analysis solely on the basis of good chromosome morphol-
ogy. In general, the technologist should select an area of the 
slide to begin the analysis and then examine metaphase cells as 
they appear consecutively in the microscope field, only skipping 
cells for which extremely poor morphology precludes chromo-
some identification. This technique can also be performed using 
automated metaphase finders by examining metaphase cells 
consecutively captured by the system. Sufficient cells should be 
analyzed or examined to maximize the detection of an abnormal 
clone and establish the clonality of the abnormality found. For 
each abnormal clone identified, clonal cells with the best chro-
mosome morphology should be analyzed, captured, and karyo-
typed to provide the most accurate breakpoint assignment.
When cells are skipped because of poor morphology, it is 
important to attempt to count the number of chromosomes. 
This is particularly true for possible hyperdiploid or hypodiploid 
pediatric ALL and hyperdiploid plasma cell dyscrasias. In addi-
tion, attempts should be made to identify possible structural 
chromosomal abnormalities, particularly if the disease under 
consideration is associated with a specific recurring abnormal-
ity (e.g., the t(9;22) in chronic myeloid leukemia (CML)).
6.3.1.2 Number of cells evaluated: The number of metaphase 
cells analyzed versus the number of cells counted or scored 
should be appropriate for the type of the study (e.g., initial diag-
nosis or follow-up studies) and the purpose of the study (e.g., 
detection of residual disease or response to therapy, monitor-
ing for clonal evolution, or monitoring of allogeneic transplant 
engraftment).
6.3.1.3 Initial diagnostic studies:
a. Analysis: Analyze a minimum of 20 cells from unstimu-
lated cultures. For the mature B- and T-cell disorders, a 
combination of unstimulated and mitogen-stimulated 
cultures may be appropriate as described. Unstimulated 
CLL cultures infrequently yield CLL-related clonal chro-
mosomal abnormalities; however, they can reveal MDS-
related clonal abnormities since some of these patients 
might have co-morbid MDS because of either prior 
therapy or age-related. Similarly, unstimulated 24-h MM 
cultures can reveal co-morbid MDS-related clonal 
abnormalities.
b. Documentation:
• For the abnormal cells:
- If only one abnormal clone is present: two 
karyotypes.
- If more than one related abnormal clone is pres-
ent: two karyotypes of the stemline and one of 
each sideline.
- If unrelated clones are present: two karyotypes 
for each stemline and one for each associated 
pertinent sideline.
- In instances when the sideline contains complex 
abnormalities, two karyotypes of each sideline 
may be required for better documentation.
•  For the normal cells:
- If only normal cells are present: two karyotypes.
- If normal and abnormal cells are present: one 
karyotype of a normal cell.
6.3.1.4 Follow-up studies of patients who have had a previ-
ous cytogenetic study: For the following analytic guidelines, it is 
assumed that the laboratory has documentation of the patient’s 
previous cytogenetic results. If the study has been performed 
elsewhere and there is minimal information available, it is 
recommended that, except for patients seen for the first time 
posttransplant, the analysis be considered the same as an initial 
diagnostic workup (see above).
I. Patients who have not undergone allogeneic hematopoi-
etic cell transplantation:
a. Analysis: analyze 20 cells. If all cells are normal, addi-
tional cells may be scored for a specific abnormality 
by G-banding or FISH if pathology is positive for the 
diagnosis in question. For some patients, follow-up 
cytogenetic study is ordered to rule out a therapy-
associated malignancy (e.g., MDS) rather than disease 
recurrence.
b. Documentation:
•  For cases with both normal and abnormal cells 
or only abnormal cells:
- One karyotype of a normal cell, if such a 
karyotype was not documented in a previ-
ous study by the laboratory; otherwise, one 
normal metaphase spread.
- One or two karyotypes from each abnormal 
clone for a minimum total of two karyotypes.
• For cases with all normal cells:
- Two karyotypes.
II. Patients who have undergone an allogeneic hematopoi-
etic cell transplantation for whom donor versus recipient 
origin of the cells can be determined (by sex chromo-
some complement or cytogenetic heteromorphisms):
For studies aimed solely at determining engraftment status, 
molecular methods and/or interphase FISH (in the case of oppo-
site sex transplant) are more sensitive than G-banded chromo-
some analysis and are the preferred methodologies. Therefore, 
in consultation with the referring physician, cancellation of test 
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requests for G-banded chromosome analysis for engraftment 
status should be considered.
During the course of the cytogenetic analysis, it will become 
evident whether there is chimerism for donor and recipient 
cells. It is expected that there will be different approaches used 
by different laboratories to address these studies.
• If only donor cells are present:
a. Analysis: analyze 20 cells.
b. Documentation: document two karyotypes for each 
cell line. In such cases, one is documenting either the 
constitutional karyotype (normal or abnormal of the 
donor) or the rare event of a malignant process aris-
ing in a donor cell.
• If donor and recipient cells are present:
a. Analysis: Analyze recipient cells completely for pre-
viously identified clonal chromosome abnormalities 
and any newly acquired abnormalities. In some cases 
there may be structural chromosomal abnormalities 
secondary to chromosome breakage or rearrange-
ment induced by the pretransplant conditioning reg-
imen. The laboratory should distinguish clonal from 
nonclonal changes and determine the significance of 
new abnormalities as much as possible.
 Analyze all recipient cells present out of 20 cells ana-
lyzed. Evaluate each recipient cell for the presence 
of the abnormality present prior to transplantation 
(i.e., the diagnostic abnormality). Depending on the 
number of recipient cells present among the initial 
20 metaphase cells scored, additional recipient cells 
may be analyzed completely and/or scored for the 
presence of the diagnostic abnormality.
 Donor cells: analyze two donor cells if donor cells have 
not been analyzed in previous studies. Otherwise, sim-
ply score these cells as being of donor origin and count.
b. Documentation: for the recipient cells: Two karyo-
types of the stemline and one of each sideline. For 
the donor cells: If donor cells have been documented 
previously, then provide a single metaphase spread. 
If donor cells have not been documented previously, 
then provide two karyotypes.
• If only recipient cells are present:
a. Analysis: analyze 20 cells following the guidelines set 
forth above with respect to the characterization of 
secondary abnormalities.
b. Documentation: same as noted above for abnormal 
recipient cells.
III. Patients who have undergone an allogeneic hematopoi-
etic cell transplantation for whom donor and recipient 
cells cannot be determined:
 Analysis: analyze 20 cells. As in case scenarios outlined 
here, follow guidelines for recipient cells as set forth 
above.
6.3.2 FISH analysis
6.3.2.1 Interphase FISH analysis may be used as a primary 
testing methodology in conjunction with G-banded chromo-
some analysis for the evaluation of hematological neoplasms. 
FISH studies may be indicated to (i) provide a rapid result to aid 
in the differential diagnosis or planning of therapy; (ii) detect 
a cryptic chromosomal abnormality or gene rearrangement, 
especially when G-banded chromosome analysis yields nor-
mal results; (iii) detect clinically significant gene amplification, 
which may also require metaphase FISH analysis to document 
the tandem nature of this rearrangement on the same chromo-
some or the presence of double minutes; (iv) provide an alterna-
tive diagnostic method when no metaphase cells are obtained 
by blood or bone marrow cultures; and (v) detect abnormalities 
in samples that are not adequate or not suitable for G-banded 
chromosome analysis.
6.3.2.2 Characterization of the initial diagnostic interphase 
FISH abnormal signal pattern is important and will allow future 
monitoring of the patient’s disease.
6.3.2.3 Metaphase FISH analysis and/or sequential G-banded 
chromosome analysis to metaphase FISH analysis may be use-
ful and provides a useful methodology to characterize variant 
chromosomal abnormalities or gene rearrangements as dem-
onstrated by a variant abnormal interphase FISH signal pattern.
6.3.2.4 Analysis and documentation of FISH studies should 
be in accordance with Section E9 of these standards and guide-
lines for clinical genetics laboratories.
6.3.3 CMA analysis
6.3.3.1 CMA analysis can add valuable information that 
will support and supplement both G-banded chromosome 
analysis and FISH. It can detect small cryptic clinically sig-
nificant copy number changes (CNCs) in various hemato-
logical neoplasms. Additionally, CMA SNP platforms can 
also detect copy-neutral loss of heterozygosity (cnLOH). 
However, this technology cannot detect balanced chromo-
somal rearrangements.
6.3.3.2 The clinical utility of genome-wide CMAs in cancer 
diagnostics is growing rapidly. This technology is being used to 
better identify high-risk patients and predict clinical outcomes. In 
view of the rapid introduction of CMAs into clinical practice, it is 
important that laboratories stay up-to-date with this technology.
6.3.3.3 Analysis and documentation of CMA studies should 
be in accordance with Section E11 of these standards and 
guidelines for clinical genetics laboratories.
6.3.4 Recommended cytogenetic analysis scheme in 
hematological neoplasms
6.3.4.1 Acute leukemias
Bone marrow is the preferred specimen for acute leukemias, 
but peripheral blood can be used when >10% circulating blast 
cells are present.8 Interphase FISH analysis performed on bone 
marrow smears or core biopsy touch imprints is an alterna-
tive in cases with a dry tap and/or hemodiluted bone marrow 
aspirate and absent/low circulating blast cells. A strong col-
laboration with the oncologist and pathologist is important for 
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establishing the order of testing and additional tests that should 
be undertaken.9
1. AML
- G-banded chromosome analysis should prefer-
ably be performed first. However, interphase FISH 
analysis for KMT2A (MALL) gene rearrangement is 
highly recommended on all diagnostic AML sam-
ples because these abnormalities are often cryptic 
and have a pronounced prognostic impact.
- In case of a successful normal chromosome analysis 
with a clear diagnosis of AML by morphology and 
flow cytometry, additional interphase and meta-
phase FISH analyses are recommended to exclude 
cryptic rearrangements. Depending on the mor-
phology and flow cytometry results, the following 
FISH probes can be added:
a. RUNX1-RUNX1T1 (AML1-ETO) fusion probes
b. CBFB rearrangement or CBFB-MYH11 fusion 
probes: inv(16) and t(16;16) resulting in CBFB-
MYH11 fusion can be subtle in cases with sub-
optimal G-banded chromosomes quality
c. KMT2A (MLL) rearrangement probes
d. PML-RARA fusion probes: PML-RARA fusion 
is diagnostic of acute promyelocytic leukemia 
(APL), which is usually strongly suspected at 
diagnosis based on the patient’s presentation 
and blast cell morphology. A RARA break-apart 
probe can be used to detect variant transloca-
tions in which RARA fuses with a different 
partner
- In case of an incomplete/unsuccessful chromosome 
analysis or if the laboratory is unable to maintain a 
short TAT for chromosome analysis, then the fol-
lowing probes can be bundled in an AML FISH 
panel, which should be performed on the diagnostic 
specimen:
a. RUNX1-RUNX1T1 (AML1-ETO) fusion probes
b. CBFB rearrangement or CBFB-MYH11 fusion 
probes
c. KMT2A (MLL) rearrangement probes
d. –5/5q– probes
e. –7/7q– probes
f. PML-RARA fusion probes: if there is suspicion 
of APL based on the patient’s presentation and 
blast cell morphology
- MECOM (EVI1) rearrangement probes should be 
considered when chromosome analysis is suggestive 
of an inv(3) or t(3;3).
- Recent CMA studies revealed acquired CNCs and 
region of cnLOH that add independent prognostic 
impact in AML. CMA analysis can detect CNCs that 
are more specific to primary AML, whereas others 
are more specific to therapy-related AML.10 In addi-
tion, regions of cnLOH are more often detected in 
patients with normal karyotypes than with abnor-
mal karyotypes.11,12
2. ALL
- B-lineage ALL is more frequent, accounting for 85% 
of pediatric ALL and 75% of adult ALL.1
- In pediatric/young adult B-lineage ALL, G-banded 
chromosome analysis should be performed simulta-
neously with interphase FISH analysis using a panel 
that includes the following probes:
a. BCR-ABL1 fusion probes
b. KMT2A (MLL) rearrangement probes
c. ETV6-RUNX1 fusion probes: for ETV6-RUNX1 
fusion, ETV6 deletion, and iAMP21 (intrachro-
mosomal amplification of chromosome 21)
d. Centromeric probes for chromosomes 4 and 10: 
for trisomies of chromosomes 4 and 10
- In adult B-lineage ALL, G-banded chromosome 
analysis should be performed simultaneously with 
interphase FISH analysis using the following probes:
a. BCR-ABL1 fusion probes
b. KMT2A (MLL) rearrangement probes
- In both pediatric and adult B-lineage ALL, and 
depending on the blast cell morphology, flow cytom-
etry, chromosome analysis, and FISH results, addi-
tional interphase FISH testing should be considered, 
including:
a. CRLF2 rearrangement probes: for P2RY8-
CRLF2 fusion and IGH-CRFL2 fusion (Ph-like 
ALL)13
b. PDGFRB rearrangement probes (Ph-like ALL)13
c. CDKN2A/B (9p21.3) probe: 9p21.3 deletion is 
common in both B- and T-lineage ALLs, but its 
prognostic significance has been debated; how-
ever, it provides a clonal target for future moni-
toring of the patient’s disease in the absence of 
other FISH targets
d. PAX5 (9p13.2) probe
- MYC rearrangement and/or IGH-MYC fusion 
probes should be considered in both pediatric and 
adult ALL, where the morphology and flow cytom-
etry results are suggestive of B-cell ALL (Burkitt leu-
kemia variant)
- In T-lineage ALL, G-banded chromosome analysis 
should be performed first. Interphase FISH analysis 
is optional and could include the following probes:
a. BCR-ABL1 fusion probes: for BCR-ABL1 fusion 
and ABL1 amplification
b. KMT2A (MLL) rearrangement probes
- In ALL, CMA analysis can be very helpful for 
detecting cryptic CNCs, with proven relevance to 
diagnosis, prognosis, and therapeutic response.14–16 
Examples include deletions involving PAX5 and 
IKZF1 genes. It can also help clarify the structure 
of complex chromosomal rearrangements. Finally, 
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CMA SNP platforms can detect whole-chromosome 
cnLOH due to “doubling” of a near-haploid or low 
hypodiploid clone, which manifests in the form of a 
hyperdiploid or near-triploid karyotype. The prog-
nosis of these two entities is very different.
6.3.4.2 Myelodysplastic syndromes
- Bone marrow is the preferred specimen for MDS.17 
Interphase FISH analysis performed on bone marrow 
smears or core biopsy touch imprints is an alternative in 
cases with a dry tap and/or hemodiluted bone marrow 
aspirate. A strong collaboration with the oncologist and 
pathologist is important in MDS cases, where other non-
neoplastic hematological disorders can have a similar 
presentation.
- G-banded chromosome analysis should preferably be 
performed first. In case of an incomplete/unsuccessful 
chromosome analysis or if the laboratory is unable to 
maintain a short TAT for chromosome analysis, the fol-
lowing probes can be bundled in an MDS FISH panel,18 
which should be performed on the diagnostic specimen:
a. -5/5q- probes
b. -7/7q- probes
c. Centromeric probe for chromosome 8: for trisomy 8
d. 20q- probe
- Recent data suggest that MDS exhibits abundant clonal 
CNCs and cnLOH, often in the setting of a normal 
metaphase karyotype and with no previously identified 
clonal markers. CMA analysis is proving to be very use-
ful in uncovering these genomic aberrations in MDS.19,20 
Examples include cryptic 5q deletions distal to the EGR1 
gene (5q31). These can be missed by G-banded chromo-
some and FISH analyses.21
6.3.4.3 Myeloproliferative neoplasms and myelodysplastic 
syndromes/myeloproliferative neoplasms.
This is a hetero geneous group of clonal stem disorders that is 
broadly divided into three groups.9,22 The first is the classical 
MPN group, which includes CML (BCR-ABL1 fusion posi-
tive), polycythemia vera, essential thrombocythemia, primary 
myelofibrosis, chronic neutrophilic leukemia, chronic eosino-
philic leukemia not otherwise specified, mastocytosis, and 
MPN unclassified. The second group includes myeloid and 
lymphoid neoplasms associated with eosinophilia and abnor-
malities of PDGFRA, PDGFRB, or FGFR1. The third is the 
MDS/MPN group, which includes chronic myelomonocytic 
leukemia, atypical CML (BCR-ABL1 fusion negative), juvenile 
myelomonocytic leukemia, and MDS/MPN unclassified.
1. CML
- Bone marrow is the preferred specimen for CML; 
however, peripheral blood may be used if the level of 
blasts is >10%.
- The t(9;22)(q34;q11.2) is detectable in 90–95% of 
CML cases at diagnosis. The remaining 5–10% of 
cases have either a variant t(9;22) or a cryptic BCR-
ABL1 fusion undetectable by chromosome analysis.
- Therefore, both G-banded chromosome analysis as 
well as interphase FISH analysis using BCR-ABL1 
fusion probes should be performed simultaneously 
at diagnosis.
- It is important to establish whether additional chro-
mosome abnormalities are present at diagnosis, 
including an additional der(22), i(17q), and trisomy 
8. These are warning signs that might be associated 
with inferior overall survival and increased risk of 
progression to accelerated phase.23,24
- The CML National Comprehensive Cancer Network 
(NCCN) guidelines recommend that cytogenetic 
studies (both G-banded chromosome and BCR-
ABL1 fusion FISH analyses) and quantitative 
RT-PCR BCR-ABL1 fusion testing be performed at 
diagnosis. If no BCR-ABL1 fusion can be detected, 
molecular testing for mutations associated with 
other myeloproliferative conditions is indicated.
2. Other MPNs
- Bone marrow is the preferred specimen for other 
MPNs; however, peripheral blood may be used if 
there is peripheral involvement. With few excep-
tions, cytogenetic abnormalities are usually not 
specific in other MPNs. Typical abnormalities of 
myeloid neoplasms are usually observed and can be 
useful in demonstrating evidence of clonality.
- Interphase FISH analysis performed on bone mar-
row smears or core biopsy touch imprints is an alter-
native in cases with a dry tap and/or hemodiluted 
bone marrow aspirate. A strong collaboration with 
the oncologist and pathologist is important.
- The exclusion of BCR-ABL1 fusion is necessary for 
the differential diagnosis of other MPNs from CML.
- Other specific FISH probes recommended in other 
MPNs based on the pathology input include FIP1L1-
PDFGRA fusion, PDGFRB rearrangement, and 
FGFR1 rearrangement probes in myeloid/lymphoid 
neoplasms with eosinophilia. MPNs with these gene 
rearrangements can be treated with targeted thera-
pies (i.e., tyrosine kinase inhibitors).
6.3.4.4 Plasma cell dyscrasias
- A bone marrow specimen is required for MM. For FISH 
and/or CMA analyses, plasma cell separation is recom-
mended to enrich for the CD138+ plasma cell fraction in 
bone marrow samples with low plasma cell percentages 
(see Section 6.2.2.3).4,5
- G-banded chromosome analysis should be performed (as 
described above) simultaneously with interphase FISH 
analysis using a panel that includes the following probes:25–27
a. 1q21.3 probe (including CKS1B): for 1q21 copy gain, 
which has been linked to adverse prognosis
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b. 13q14.2q14.3 probes (including RB1): 13q14.2q14.3 
deletion is common in MM but, when detected only 
by FISH, it is not predictive of survival in the absence 
of other adverse cytogenetic abnormalities. However, 
it provides a clonal target for future monitoring of 
the patient’s disease in the absence of other FISH 
targets. 13q deletion detected by G-banded chromo-
some analysis still retains its prognostic value
c. IGH rearrangement probes: if IGH is rearranged, 
including the classical gene disruption as well as 
deletion of either the 5′ or 3′ region of IGH, then 
reflex to IGH-FGFR3, IGH-CCND1, and IGH-MAF 
fusion probes.
d. TP53 (17p13.1) probe
e. Probes for three of the odd-numbered chromosomes 
often trisomic in hyperdiploid MM (e.g., chromo-
somes 5, 9, 11, 15, and 19)
- The use of CMA analysis on the enriched plasma cell 
fraction has been shown to be very valuable in detecting 
clinically relevant CNCs.28–30
6.3.4.5 Chronic lymphocytic leukemia
- CLL is a mature B-cell neoplasm diagnosed by B-cell 
count, morphology, and flow cytometry. Cytogenetically, 
either peripheral blood or bone marrow can be used 
in CLL. G-banded chromosome analysis should be 
performed simultaneously with interphase FISH 
analysis.31 CLL cell stimulation in culture using CpG-
oligonucleotides greatly improves the detection rate of 
clonal cytogenetic abnormalities by G-banded chromo-
some analysis.6,7
- To assign the patient into clinically relevant prognos-
tic subgroups, the following panel of FISH probes is 
recommended:
a. ATM (11q22.3) probe
b. Centromeric probe for chromosome 12: for trisomy 
12
c. 13q14.3 probe (including D13S319)
d. TP53 (17p13.1) probe
- FISH can also be useful for the differential diagnosis with 
mantle cell lymphoma (MCL), for which FISH using the 
IGH-CCND1 fusion probes is recommended.
- In CLL, CMA analysis has proven to be very effective 
in detecting CNCs and cnLOH at genomic regions with 
established prognostic significance, and it provides a much 
higher resolution compared to G-banded chromosome 
and FISH analyses.32,33 Examples include 13q14 deletions, 
which are quite heterogeneous.34 Moreover, clinically rel-
evant genomic alterations in CLL involve mostly deletions 
and duplications, whereas most balanced translocations 
are relatively rare and are of unclear significance.
6.3.4.6 B- and T-cell lymphomas
- For all lymphomas, the preferred tissue is lymph node or 
biopsy material from a suspected lymphoid mass. If fresh 
material is available, G-banded chromosome analysis is 
recommended.
- Interphase FISH analysis using relevant probes per-
formed on lymph node tissue sections, fine needle aspi-
rate smears, and/or touch imprints should be included.
- For lymph node cytogenetic analysis in lymphomas, see 
Section E6.5-6.8.
- Bone marrow or peripheral blood analysis will not detect 
clonal chromosomal abnormalities if there is no evidence 
of infiltration. For FISH analysis, bone marrow smears or 
core biopsy touch imprints can be used.
6.4 TAT AND REPORTING
6.4.1 TAT 
6.4.1.1 Specific chromosomal abnormalities are crucial for 
establishing a diagnosis and have direct relevance to specific 
treatment. Therefore, an effort should be made to expedite 
communicating the cytogenetic analyses results to the oncolo-
gist. It is recommended that the cytogenetics laboratory should 
have a written policy describing how cases are prioritized in the 
laboratory.
6.4.1.2 TAT guidance:
a. Initial diagnostic workup: It is strongly recommended 
that the preliminary result should be reported within 7 
calendar days, and the final results should be reported 
within 21 calendar days.
b. Follow-up studies: It is strongly recommended that the 
final results should be reported within 21 calendar days.
c. FISH studies: Reporting the FISH results within 3–5 
working days from the time of receiving the specimen is 
recommended whenever possible.
6.4.2 Reporting
6.4.2.1 The most recent edition of the International System for 
Human Cytogenetic Nomenclature (ISCN) should be used to 
report the cytogenetics results.35
6.4.2.2 The number of cells analyzed (both normal and 
abnormal) should be documented in the final report.
6.4.2.3 For CMA analysis, clones and subclones cannot be 
ascertained with certainty; however, the percentage of cells 
(levels of mosaicism) can be provided to give an estimate of 
possible clones/subclones and clonal diversity.
6.4.2.4 If a potential nonmosaic constitutional abnormality is 
observed, analysis of a PHA-stimulated peripheral blood sam-
ple during remission is strongly recommended to confirm that 
the abnormality is constitutional and not clonal.
6.4.2.5 At the time of initial diagnosis, finding a single abnor-
mal metaphase cell, even one that is potentially significant, 
cannot be used as evidence of clonality unless there is strong 
supporting evidence of clonality for the same abnormality by 
either FISH or other molecular technique.
6.4.2.6 The final cytogenetic report of hematological acquired 
chromosomal abnormalities should contain the following 
information:
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1. Patient identification using two different identifiers
2. Patient medical record number and/or laboratory identi-
fication number
3. Referring physician
4. Sample information (type, date of withdrawal and 
receipt, and date of report)
5. Reason for referral or suspected diagnosis
6. ISCN nomenclature of cytogenetic studies performed
7. Narrative description of the abnormalities observed, 
including modal chromosome number in each clone 
(to the extent possible), and numerical and structural 
abnormalities. The report should comment on the clini-
cal significance of the abnormalities observed, including 
clinically relevant genes involved, possible disease asso-
ciation, and prognostic significance.
8. Literature references to support the clinical interpretation 
and to provide helpful information for the oncologist.
DISCLOSURE
All of the authors direct clinical cytogenetics laboratories that run 
the tests discussed in the current standards and guidelines on a 
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